Zacks: Neon Therapeutics Inc (NTGN) Given $20.25 Average Price Target by Brokerages
Shares of Neon Therapeutics Inc (NASDAQ:NTGN) have been given an average broker rating score of 1.13 (Strong Buy) from the four analysts that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a buy rating and three have given a strong buy rating to the company. Neon Therapeutics’ rating score has improved by 3.4% from three months ago as a result of a number of analysts’ upgrades and downgrades.
Brokerages have set a 1-year consensus price objective of $20.25 for the company and are anticipating that the company will post ($0.79) EPS for the current quarter, according to Zacks. Zacks has also given Neon Therapeutics an industry rank of 105 out of 255 based on the ratings given to its competitors.
Several analysts have weighed in on the company. LADENBURG THALM/SH SH assumed coverage on Neon Therapeutics in a research report on Monday, October 1st. They set a “buy” rating and a $20.00 price objective on the stock. Cann reaffirmed a “buy” rating and set a $20.00 price objective on shares of Neon Therapeutics in a research report on Tuesday, August 7th. Oppenheimer assumed coverage on Neon Therapeutics in a research report on Monday, July 23rd. They set a “$11.74” rating and a $20.00 price objective on the stock. Morgan Stanley assumed coverage on Neon Therapeutics in a research report on Monday, July 23rd. They set an “overweight” rating and a $23.00 price objective on the stock. Finally, Bank of America assumed coverage on Neon Therapeutics in a research report on Monday, July 23rd. They set a “buy” rating and a $18.00 price objective on the stock.
Neon Therapeutics stock traded up $0.31 during trading hours on Thursday, hitting $8.31. 171,500 shares of the stock traded hands, compared to its average volume of 129,728. Neon Therapeutics has a one year low of $6.17 and a one year high of $16.23.
Neon Therapeutics (NASDAQ:NTGN) last posted its quarterly earnings data on Monday, August 6th. The company reported ($7.84) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.80) by ($7.04). As a group, analysts forecast that Neon Therapeutics will post -5.5 earnings per share for the current year.
About Neon Therapeutics
Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.
Featured Article: How to calculate the intrinsic value of a stock
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.